Here's Why Royalty Pharma (NASDAQ:RPRX) Has A Meaningful Debt Burden

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will

Simply Wall St14:21

Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe

Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.

Analyst Upgrades13:30

Cytokinetics Slips 18% After It Announces Funding Collaboration With Royalty Pharma

RTTNewsMay 23 09:22

Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline

Cytokinetics (CYTK) disclosed a collaboration late Wednesday under which Royalty Pharma (RPRX) will provide capital totaling up to $575 million to support the commercialization of aficamten and advanc

MT NewswiresMay 22 16:00

Cytokinetics Falls 10% on Royalty Pharma Transaction, Stock Offer

By Josh Beckerman Cytokinetics shares were down 10%, to $53.25, after hours as the biopharmaceutical company announced an expanded funding collaboration with Royalty Pharma totaling up to $575 millio

WSJMay 22 15:35

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company's expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.

GlobeNewswireMay 22 15:10